John P. Butler - 04 Mar 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: CEO and President, Director
Signature: /s/ Carolyn M. Rucci, attorney-in-fact for John P. Butler
Issuer symbol: AKBA
Transactions as of: 04 Mar 2026
Net transactions value: +$86,588
Form type: 4
Filing time: 05 Mar 2026, 18:55:46 UTC
Previous filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Butler John P.	CEO and President, Director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE	/s/ Carolyn M. Rucci, attorney-in-fact for John P. Butler	05 Mar 2026	0001591467

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Purchase	$86,588	+69,270	+2.1%	$1.25	3,367,064	04 Mar 2026	Direct	F1, F2
holding	AKBA	Common Stock						159,928	04 Mar 2026	Held by Dorothy Butler Revocable Trust November 20, 2007

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person's purchase of Akebia Therapeutics, Inc. ("Akebia") common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 69,270 shares, with the reporting person's sale of 341,305 shares of Akebia common stock at a price of $1.39 per share on February 2, 2026 pursuant to an automatic sell-to-cover instruction solely to cover applicable withholding taxes in connection with the vesting of the reporting person's RSUs granted on January 31, 2023, 2024 and 2025. The reporting person has paid Akebia, upon settlement of the sale, $9,664.60 representing the full amount of the profit realized in connection with the short-swing transaction.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

Content

The reporting person's purchase of Akebia Therapeutics, Inc. ("Akebia") common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 69,270 shares, with the reporting person's sale of 341,305 shares of Akebia common stock at a price of $1.39 per share on February 2, 2026 pursuant to an automatic sell-to-cover instruction solely to cover applicable withholding taxes in connection with the vesting of the reporting person's RSUs granted on January 31, 2023, 2024 and 2025. The reporting person has paid Akebia, upon settlement of the sale, $9,664.60 representing the full amount of the profit realized in connection with the short-swing transaction.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.